A Study of NDI 1150-101 in Patients With Solid Tumors
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
In brief
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Key facts
- Study ID
- NCT05128487
- Run by
- Nimbus Saturn, Inc.
- People needed
- 106
- Starts
- 2021-11-05
- Expected to finish
- 2025-05-01
- Last updated by the study team
- 2024-11-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Honor Health Research Institute — Scottsdale, Arizona, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Georgetown University — Washington D.C., District of Columbia, United States
- Ocala Oncology Center — Ocala, Florida, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States
- Henry Ford Cancer — Detroit, Michigan, United States
- HealthPartners Cancer Research Center — Saint Paul, Minnesota, United States
- Washington University — St Louis, Missouri, United States
- Hackensack University — Hackensack, New Jersey, United States
- Columbia University Irving Medical Center — New York, New York, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
- Center for Oncology and Blood Disorders — Houston, Texas, United States
- Oncology Consultants — Houston, Texas, United States
- NEXT Oncology — San Antonio, Texas, United States
- NEXT Oncology — Fairfax, Virginia, United States
- Northwest Medical Specialties — Tacoma, Washington, United States
- University of Wisconsin — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.